Abstract
Objectives
To measure tissue levels of bisphenol A (BPA) in uterine leiomyoma (ULM), adjacent myometrium (Myo-F), and normal myometrium (Myo-N). Also, we tested the effect of BPA treatment on rat myometrium.
Methods
Uterine leiomyomas and Myo-F tissues were isolated from hysterectomy specimens done to treat symptomatic ULMs (N = 30). Normal myometrium is isolated from hysterectomies done on ULM-free uteri for other benign indications (N = 25). Bisphenol A was measured in 1 g of tissue using solid-phase extraction and high-performance liquid chromatography, with fluorescence detectors. Experimentally, adult female rats were fed BPA orally at a dose of 50 mg/kg/d for 90 days. Animals were killed, and their myometrial thickness and proliferating cell nuclear antigen (PCNA) immunostaining were evaluated.
Results
Tissue concentration of BPA in each of ULM (12.3 ± 2.8 µg/g) and Myo-F (10.1 ± 0.2 µg/g) was significantly higher than that of Myo-N (0.58 ± 0.2 µg/g). There was no statistically significant difference in BPA level between ULM and Myo-F within submucous or interstitial/subserous fibroid groups. Compared to control rats, BPA-treated animals showed significantly higher myometrial thickness (168.67 ± 5.7 µm and 281.6 ± 20.32 µm, respectively, P = .003) and increased myometrial PCNA immunoscores (1.5 ± 0.37 and 10.38 ± 0.67, respectively, P ≤ .001).
Conclusion
Bisphenol A concentrates in human ULM tissue and its adjacent Myo-F compared to Myo-N. No significant difference is detected in BPA content of ULM tissue of different subtypes. Bisphenol A increases thickness and induces cellular proliferation in rat myometrium. Taken together, our results support a role of BPA in ULM development/growth.
Similar content being viewed by others
References
Bulun S. Uterine fibroids. N Engl J Med. 2013; 369(14):1344–1355.
Cramer SF, Patel A. The frequency of uterine leiomyoma. Am J Clin Pathol. 1990; 94(4):435–438.
Othman ER, Al-Hendy A. Molecular genetics and racial disparities in uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2008; 22(4):589–601.
Segars JH, Parrott EC, Nagel JD, et al. Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research:comprehensive review, conference summary and future recommendations. Hum Reprod Update. 2014; 20(3):309–333.
Islam MS, Protic O, Stortoni P, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013; 100(1):178–193.
Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007; 87(4):725–736.
Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual costs of uterine leiomyomas in the United States. Am J Obstet Gynecol. 2012; 206(3):e211.–e9.
Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997; 90(6):967–873.
Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998; 70(3):432–439.
Lethaby A, VoUenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001; 2:CD000547.
Pohl O, Osterloh I, Gotteland J. Ulipristal acetate—safety and pharmacokinetics following multiple doses of 10–50 mg per day. J Clin Pharm Ther. 2013; 38(4):314–320.
Horak P, Mara M, Dundr P, et al. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol. 2012; 2012:436174.
Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015; 103(2):519–27.
Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol. 1995; 146:1568–1579.
Han MS, Byun JC, Park JE, Kim JY, Chung JY, Kim JM. Bisphenol-A concentrations from leiomyoma patients by LC/ MS. Toxicol Res. 2011; 27(1):49–52.
Brotons JA, Olea-Serrano MF, Villalobos M, Pedraza V, Olea N. Xenoestrogens released from lacquer coatings in food cans. Environ Health Perspect. 1995; 103(6):608–612.
Caserta D, Mantovani A, Marci R, et al. Environment and women’s reproductive health. Human Reprod Update. 2011; 17:418–33.
Wetherill YB, Akingbemi BT, Kanno J, et al. In vitro molecular mechanisms of bisphenol A action. Reprod Toxicol. 2007; 24(2):178–88.
Caserta D, Di Segni N, Mallozzi M, et al. Bisphenol A and the female reproductive tract:an overview of recent laboratory evidence and epidemiological studies. Reprod Biol Endocrinol. 2014; 12:37.
Nagel SC, Hagelbarger JL, McDonnell DP. Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and xenobiotics. Endocrinol. 2001; 142(11):4721–4728.
Trabert D, De Roos AJ, Schwartz SM, et al. Non-dioxin-like poly-chlorinated biphenyls and risk of endometriosis. Environ Health Perspect. 2010; 118(9):1280–1285.
Louis GMB. Persistent lipophilic environmental chemicals and endometriosis:the ENDO study. Environ Health Perspect. 2012; 120(6):811–816.
Kandaraki E, Chatzigeorgiou A, Livadas S, et al. Endocrine dis-ruptors and polycystic ovary syndrome (PCOS):elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab. 2011; 96(3):E480–E484.
Rutkowska A, Rachon D. Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2014; 30(4):260–265.
Xiao Q, Li Y, Ouyang H, Xu P, Wu D. High-performance liquid chromatographic analysis of bisphenol A and 4-nonylphenol in serum, liver and testis tissues after oral administration to rats and its application to toxicokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 830(2):322–329.
Schönfelder G, Friedrich K, Paul M, Chahoud I. Developmental effects of prenatal exposure to bisphenol a on the uterus of rat offspring. Neoplasia. 2004; 6(5):584–594.
Jefferson WN, Padilla-Banks E, Newbold RR. Disruption of the female reproductive system by the phytoestrogen genistein. Reprod Toxicol. 2007; 23(3):308–316.
Pollack AZ, Buck Louis GM, Chen Z, et al. Bisphenol A, benzophenone-type ultraviolet filters, and phthalates in relation to uterine leiomyoma. Environ Res. 2015; 137:101–107.
Shen Y, Xu Q, Ren M, Feng X, Cai Y, Gao Y. Measurement of phenolic environmental estrogens in women with uterine leiomyoma. PLoS One. 2013; 8(11):79838.
Zhou F, Zhang L, Liu A, et al. Measurement of phenolic environmental estrogens in human urine samples by HPLC-MS/MS and primary discussion the possible linkage with uterine leiomyoma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 938:80–85.
Weuve J, Hauser R, Calafat AM, Missmer SA, Wise LA. Association of exposure to phthalates with endometriosis and uterine leiomyomata:findings from NHANES, 1999–2004. Environ Health Perspect. 2010; 118(6):825–832.
Yu L, Moore AB, Castro L, et al. Estrogen regulates MAPK-related genes through genomic and nongenomic interactions between IGF-1-I receptor tyrosine kinase and estrogen receptor-alpha signaling pathways in human uterine leiomyoma cells. J Signal Transduct. 2012; 2012:204236.
Ishikawa H, Ishi K, Sema VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010; 151(6):2433–2442.
Richter C, Bimbaum L, FaraboUini F, et al. in vivo effects of bisphenol A in laboratory rodent studies. Reprod Toxicol. 2007; 24(2):199–224.
Monje L, Varayoud J, Munoz-de-toro M, Luque EH, Ramos JG. Exposure of neonatal female rats to bisphenol A disrupt hypothalamic LHRH pre-mRNA processing and estrogen receptor alpha expression in nuclei controlling estrous cycli-city. Reprod Toxicol. 2010; 30(4):625–634.
Lee SG, Kim JY, Chung JY, et al. Bisphenol A exposure during adulthood causes augmentation of follicular atresia and luteal regression by decreasing 17P-estradiol synthesis via downregula-tion of aromatase in rat ovary. Environ Health Perspect. 2013; 121(6):663–669.
Kandaraki E, Chatzigeorgiou A, Livadas S, et al. Endocrine dis-ruptors and polycystic ovary syndrome (PCOS):elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab. 2011; 96(3):480–484.
Shen Y, Ren ML, Feng X, Cai YL, Gao YX, Xu Q. An evidence in vitro for the influence of bisphenol A on uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol. 2014; 178:80–83.
Fernández M, Bourguignon N, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol a and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environ Health Perspect. 2010; 118(9):1217–1222.
Newbold RR, Jefferson WN, Padilla-Banks E. Long-term adverse effects of neonatal exposure to bisphenol A on the murine female reproductive tract. Reprod Toxicol. 2007; 24(2):253–258.
Grain DA, Janssen SJ, Edwards TM, Heindel J, Ho SM, Hunt P. Female reproductive disorders:the roles of endocrine-disrupting compounds and developmental timing. Fertil Steril. 2008; 90(4):911–840.
Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals:an Endocrine Society scientific statement. Endocr Rev. 2009; 30(4):293–342.
Greathouse KL, Bredfeldt T, Everitt JI, et al. Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis. Mol Cancer Res. 2012; 10(4):546–57 doi:https://doi.org/10.1158/1541-7786.MCR-11-0605.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Othman, E.R., Al-Adly, D.M.M., Elgamal, D.A. et al. Bisphenol A Concentrates Preferentially in Human Uterine Leiomyoma and Induces Proliferation in Rat Myometrium. Reprod. Sci. 23, 508–514 (2016). https://doi.org/10.1177/1933719115608001
Published:
Issue Date:
DOI: https://doi.org/10.1177/1933719115608001